As of June 30, 2025, Cabaletta had cash, cash equivalents and short-term investments of $194.7 million, compared to $164.0 million as of December 31, 2024. The Company expects that its cash position as of June 30, 2025, will enable it to fund its operating plan into the second half of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio’s Promising Study on CABA-201 for Myasthenia Gravis: A Potential Game-Changer
- Cabaletta Bio’s RESET-SLE Study: A Promising Step in Lupus Treatment
- Cabaletta Bio’s RESET-MG Study: A Potential Game-Changer for Myasthenia Gravis Treatment
- Cabaletta Bio’s RESET-Myositis Study: A Promising Step in Autoimmune Treatment
- Cabaletta Bio’s RESET-MG Study: A Promising Step in Myasthenia Gravis Treatment